Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study

Abstract

BackgroundThe purpose of this study was to evaluate the distribution of glioma-related seizures and seizure control at the time of tumor diagnosis with respect to tumor histologic subtypes, tumor treatment and patient characteristics, and to compare seizure history preceding tumor diagnosis (or study enrollment) between glioma patients and healthy controls.MethodsThe Glioma International Case Control study (GICC) risk factor questionnaire collected information on demographics, past medical/medication history, and occupational history. Cases from eight centers were also asked detailed questions on seizures in relation to glioma diagnosis; cases (n = 4533) and controls (n = 4171) were also asked about seizures less than 2 years from diagnosis and previous seizure history more than 2 years prior to tumor diagnosis, including childhood seizures.ResultsLow-grade gliomas (LGGs), particularly oligodendrogliomas/oligoastrocytomas, had the highest proportion of glioma-related seizures. Patients with low-grade astrocytoma demonstrated the most medically refractory seizures. A total of 83% of patients were using only one antiepileptic drug (AED), which was levetiracetam in 71% of cases. Gross total resection was strongly associated with reduced seizure frequency (p < 0.009). No significant difference was found between glioma cases and controls in terms of seizure occurring more than 2 years before diagnosis or during childhood.ConclusionsOur study showed that glioma-related seizures were most common in low-grade gliomas. Gross total resection was associated with lower seizure frequency. Additionally, having a history of childhood seizures is not a risk factor ***for developing glioma-related seizures or glioma.

Long non‑coding RNA LINC00473/miR‑195‑5p promotes glioma progression via YAP1‑TEAD1‑Hippo signaling

“…Glioma is considered as one of most aggressive malignancies in central nervous system worldwide; it is clinically complicated due to various pathogenic genes and proteins (28,29). lncRNAs are key regulators in glioma pathogenesis (7), and LINC00473 has been reported to be a novel oncogene of human cancers (10,17).…”

TRIM31 promotes proliferation, invasion and migration of glioma cells through Akt signaling pathway

“…Cox's proportional hazards regression model was used for multivariate survival analysis. The Chi square (χ 2 ) test was used to analyze the relationship between TRIM31 expression and the clinicopathological features. Spearman rank correlation analysis was used to evaluate the immunohistochemistry results of TRIM31 and Ki-67.…”

“…Glioma is one of the most malignant primary tumors of the central nervous system [1], including astrocytoma, oligodendroglioma, ependymoma, anaplastic astrocytoma, glioblastoma and so on [2]. The biological feature of glioma cells is its strong ability to proliferate, migrate and invade normal adjacent tissues [3].…”

Development of a Rat Model for Glioma-Related Epilepsy

“…Brain tumor-related seizures typically have a focal onset and can be associated with alteration of consciousness and secondary generalization [ 3 ]. Up to 30% of patients with GB suffer from drug-resistant epilepsy (DRE), resulting in significant morbidity and negative impact on quality of life [ 3 , 9 , 10 , 11 ].…”